AIM: To investigate whether 18F-FDG-PET allows early assessment of response to imatinib mesylate in GIST patients. PATIENTS AND METHODS: Five gastrointestinal stromal tumour (GIST) patients and one patient with a KIT-positive small cell cancer were studied. Treatment consisted of 400 mg imatinib mesylate daily. 18F-deoxyglucose-positron emission tomography (18F-FDG-PET) scans were done before and one week after starting imatinib mesylate therapy. RESULTS: Metabolic responses were detected after only one week of therapy in all GIST patients (four partial and one complete response). The mean decrease of the standardised uptake value was 60% (range 43 to 77%). In contrast, the tumour of the non-GIST patient was metabolically stable. Four of the 5 GIST patients achieved a partial response on CT after a mean duration of 23 weeks (range 6 to 48 weeks). CONCLUSION: 18F-FDG-PET is a valuable method for the detection of response to imatinib mesylate in patients with KIT-positive tumours as early as one week after starting therapy.
AIM: To investigate whether 18F-FDG-PET allows early assessment of response to imatinib mesylate in GISTpatients. PATIENTS AND METHODS: Five gastrointestinal stromal tumour (GIST) patients and one patient with a KIT-positive small cell cancer were studied. Treatment consisted of 400 mg imatinib mesylate daily. 18F-deoxyglucose-positron emission tomography (18F-FDG-PET) scans were done before and one week after starting imatinib mesylate therapy. RESULTS: Metabolic responses were detected after only one week of therapy in all GISTpatients (four partial and one complete response). The mean decrease of the standardised uptake value was 60% (range 43 to 77%). In contrast, the tumour of the non-GISTpatient was metabolically stable. Four of the 5 GISTpatients achieved a partial response on CT after a mean duration of 23 weeks (range 6 to 48 weeks). CONCLUSION: 18F-FDG-PET is a valuable method for the detection of response to imatinib mesylate in patients with KIT-positive tumours as early as one week after starting therapy.
Authors: Annick D Van den Abbeele; Constantine Gatsonis; Daniel J de Vries; Yulia Melenevsky; Agnieszka Szot-Barnes; Jeffrey T Yap; Andrew K Godwin; Lori Rink; Min Huang; Meridith Blevins; Jorean Sicks; Burton Eisenberg; Barry A Siegel Journal: J Nucl Med Date: 2012-03-01 Impact factor: 10.057
Authors: Steve Y Cho; Evan J Lipson; Hyung-Jun Im; Steven P Rowe; Esther Mena Gonzalez; Amanda Blackford; Alin Chirindel; Drew M Pardoll; Suzanne L Topalian; Richard L Wahl Journal: J Nucl Med Date: 2017-03-30 Impact factor: 10.057
Authors: Wen Wee Ma; Heather Jacene; Dongweon Song; Felip Vilardell; Wells A Messersmith; Dan Laheru; Richard Wahl; Chris Endres; Antonio Jimeno; Martin G Pomper; Manuel Hidalgo Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544